BRPI0806262A2 - complexo insulinotrópico usando um fragmento de imunoglobulina - Google Patents

complexo insulinotrópico usando um fragmento de imunoglobulina Download PDF

Info

Publication number
BRPI0806262A2
BRPI0806262A2 BRPI0806262-5A BRPI0806262A BRPI0806262A2 BR PI0806262 A2 BRPI0806262 A2 BR PI0806262A2 BR PI0806262 A BRPI0806262 A BR PI0806262A BR PI0806262 A2 BRPI0806262 A2 BR PI0806262A2
Authority
BR
Brazil
Prior art keywords
insulinotropic
insulinotropic peptide
immunoglobulin fragment
complex
peptide conjugate
Prior art date
Application number
BRPI0806262-5A
Other languages
English (en)
Portuguese (pt)
Inventor
Dae Hae Song
Chang Ki Lim
Tae Hun Song
Young Hoon Kim
Se Chang Kwon
Gwan Sun Lee
Sung Youb Jung
In Young Choi
Original Assignee
Hanmi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharmaceutical Co Ltd filed Critical Hanmi Pharmaceutical Co Ltd
Publication of BRPI0806262A2 publication Critical patent/BRPI0806262A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0806262-5A 2007-01-05 2008-01-04 complexo insulinotrópico usando um fragmento de imunoglobulina BRPI0806262A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20070001662 2007-01-05
PCT/KR2008/000061 WO2008082274A1 (en) 2007-01-05 2008-01-04 An insulinotropic complex using an immunoglobulin fragment

Publications (1)

Publication Number Publication Date
BRPI0806262A2 true BRPI0806262A2 (pt) 2011-08-30

Family

ID=39588830

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0806262-5A BRPI0806262A2 (pt) 2007-01-05 2008-01-04 complexo insulinotrópico usando um fragmento de imunoglobulina

Country Status (20)

Country Link
US (1) US8476230B2 (https=)
EP (1) EP2114438B8 (https=)
JP (2) JP2008169195A (https=)
KR (3) KR101058290B1 (https=)
CN (3) CN103435699B (https=)
AR (2) AR065639A1 (https=)
AU (1) AU2008203574B2 (https=)
BR (1) BRPI0806262A2 (https=)
CA (1) CA2674538C (https=)
DK (1) DK2114438T3 (https=)
ES (1) ES2394121T3 (https=)
IL (1) IL199566A (https=)
MX (1) MX2009007267A (https=)
MY (1) MY164479A (https=)
NZ (1) NZ577812A (https=)
PT (1) PT2114438E (https=)
RU (1) RU2436589C2 (https=)
TW (1) TWI413528B (https=)
WO (1) WO2008082274A1 (https=)
ZA (1) ZA200904337B (https=)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8263084B2 (en) 2003-11-13 2012-09-11 Hanmi Science Co., Ltd Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate
US8110665B2 (en) * 2003-11-13 2012-02-07 Hanmi Holdings Co., Ltd. Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
KR101135244B1 (ko) 2007-11-29 2012-04-24 한미사이언스 주식회사 인슐린 분비 펩타이드 결합체를 포함하는 비만 관련질환 치료용 조성물
JP2009019027A (ja) 2007-07-16 2009-01-29 Hanmi Pharmaceutical Co Ltd アミノ末端のアミノ酸が変異したインスリン分泌ペプチド誘導体
UA101670C2 (ru) * 2008-07-23 2013-04-25 Ханми Сайенс Ко., Лтд. Полипептидный комплекс, содержащий непептидильный полимер, который имеет три функциональных конца
WO2010118384A2 (en) 2009-04-10 2010-10-14 Amylin Pharmaceuticals, Inc. Amylin agonist compounds for estrogen-deficient mammals
WO2011107990A1 (en) * 2010-03-02 2011-09-09 Protalix Ltd. Stabilized alpha-galactosidase and uses thereof
US9194011B2 (en) 2009-11-17 2015-11-24 Protalix Ltd. Stabilized alpha-galactosidase and uses thereof
AU2010321587A1 (en) 2009-11-23 2012-06-07 Amylin Pharmaceuticals, Inc. Polypeptide Conjugate
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
AR081066A1 (es) * 2010-04-02 2012-06-06 Hanmi Holdings Co Ltd Conjugado de insulina donde se usa un fragmento de inmunoglobulina
US9981017B2 (en) 2010-04-02 2018-05-29 Hanmi Science Co., Ltd. Insulin conjugate using an immunoglobulin fragment
DE102010015123A1 (de) 2010-04-16 2011-10-20 Sanofi-Aventis Deutschland Gmbh Benzylamidische Diphenylazetidinone, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
KR101324828B1 (ko) * 2010-06-08 2013-11-01 한미사이언스 주식회사 면역글로불린 단편을 이용한 단쇄 인슐린 아날로그 약물 결합체
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
KR101382593B1 (ko) * 2010-07-21 2014-04-10 한미사이언스 주식회사 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물
WO2012050923A2 (en) 2010-09-28 2012-04-19 Amylin Pharmaceuticals, Inc. Engineered polypeptides having enhanced duration of action
ES2630031T3 (es) 2010-09-28 2017-08-17 Aegerion Pharmaceuticals, Inc. Un polipéptido de leptina pinnípedo-humano quimérico con solubilidad aumentada
JP2014521594A (ja) * 2011-05-25 2014-08-28 アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー 長持続期間デュアルホルモンコンジュゲート
UA113626C2 (xx) 2011-06-02 2017-02-27 Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії
PE20240686A1 (es) 2011-06-10 2024-04-10 Hanmi Science Co Ltd Peptidos derivados de oxintomodulina con actividad sobre el receptor de glucagon y el receptor de peptido similar a glucagon de tipo 1 (glp-1)
PE20230404A1 (es) 2011-06-17 2023-03-07 Hanmi Science Co Ltd Un conjugado que comprende oxintomodulina y un fragmento de inmunoglobulina, y uso del mismo
ES2732475T3 (es) 2011-07-08 2019-11-22 Aegerion Pharmaceuticals Inc Polipéptidos modificados por ingeniería genética que tienen una duración potenciada de la acción y una inmunogenicidad reducida
JP6006309B2 (ja) 2011-07-08 2016-10-12 アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc 作用持続期間が増大し、免疫原性が減少した操作されたポリペプチド
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
KR20130049671A (ko) 2011-11-04 2013-05-14 한미사이언스 주식회사 생리활성 폴리펩타이드 결합체 제조 방법
CN103172745A (zh) * 2011-12-21 2013-06-26 北京韩美药品有限公司 包含免疫球蛋白Fc片段的长效人内皮抑素
KR101895047B1 (ko) * 2011-12-30 2018-09-06 한미사이언스 주식회사 면역글로불린 단편을 이용한 위치 특이적 글루카곤 유사 펩타이드-2 약물 결합체
KR102041412B1 (ko) 2011-12-30 2019-11-11 한미사이언스 주식회사 면역글로불린 Ｆｃ 단편 유도체
AR090281A1 (es) 2012-03-08 2014-10-29 Hanmi Science Co Ltd Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo
KR101665009B1 (ko) * 2012-03-09 2016-10-11 한미사이언스 주식회사 비알콜성 지방간 질환의 예방 또는 치료용 약학적 조성물
US10441665B2 (en) 2012-07-25 2019-10-15 Hanmi Pharm. Co., Ltd. Liquid formulation of long acting insulinotropic peptide conjugate
AR094821A1 (es) 2012-07-25 2015-09-02 Hanmi Pharm Ind Co Ltd Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada
KR101968344B1 (ko) 2012-07-25 2019-04-12 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
AR092862A1 (es) 2012-07-25 2015-05-06 Hanmi Pharm Ind Co Ltd Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion
WO2014064215A1 (en) 2012-10-24 2014-05-01 INSERM (Institut National de la Santé et de la Recherche Médicale) TPL2 KINASE INHIBITORS FOR PREVENTING OR TREATING DIABETES AND FOR PROMOTING β-CELL SURVIVAL
PE20151421A1 (es) 2012-11-06 2015-09-24 Hanmi Pharm Ind Co Ltd Formulacion liquida del conjugado de proteina que comprende la oxintomodulina y un fragmento de inmunoglobulina
KR101993393B1 (ko) 2012-11-06 2019-10-01 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
KR20140088837A (ko) * 2013-01-03 2014-07-11 한미약품 주식회사 Ｎ-말단 전하가 변형된 인슐린 분비 펩티드 유도체
TWI708782B (zh) * 2013-02-26 2020-11-01 南韓商韓美藥品股份有限公司 新穎胰島素類似物及其用途
KR101895634B1 (ko) * 2013-05-31 2018-09-05 한미약품 주식회사 변이된 힌지 영역을 포함하는 IgG4 Fc 단편
AR096891A1 (es) * 2013-07-12 2016-02-03 Hanmi Pharm Ind Co Ltd Conjugado de monómero polipéptido biológicamente activo y conjugado de fragmento fc de inmunoglobulina, que muestra aclaramiento mediado por receptor reducido, y el método para la preparación del mismo
AR096890A1 (es) * 2013-07-12 2016-02-03 Hanmi Pharm Ind Co Ltd Conjugando fc de inmunoglobulina, que mantiene la afinidad de unión del fragmento fc de la inmunoglobulina a fcrn
EP3098235A4 (en) 2014-01-20 2017-10-18 Hanmi Pharm. Co., Ltd. Long-acting insulin and use thereof
AU2015242657B2 (en) * 2014-03-31 2020-05-21 Hanmi Pharm. Co., Ltd. Method for improving solubility of protein and peptide by using immunoglobulin Fc fragment linkage
AR100639A1 (es) * 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
TWI684458B (zh) 2014-05-30 2020-02-11 南韓商韓美藥品股份有限公司 包含胰島素及ｇｌｐ-１/昇糖素雙重促效劑之治療糖尿病之組成物
KR20150140177A (ko) * 2014-06-05 2015-12-15 한미약품 주식회사 단백질 및 펩타이드의 면역원성을 감소시키는 방법
TWI802396B (zh) 2014-09-16 2023-05-11 南韓商韓美藥品股份有限公司 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途
US10046058B2 (en) * 2014-12-02 2018-08-14 Rezolute, Inc. Use of hydrophobic organic acids to increase hydrophobicity of proteins and protein conjugates
MY185334A (en) 2014-12-30 2021-05-06 Hanmi Pharm Ind Co Ltd Glucagon derivatives with improved stability
KR102418477B1 (ko) 2014-12-30 2022-07-08 한미약품 주식회사 글루카곤 유도체
US10426818B2 (en) 2015-03-24 2019-10-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Method and pharmaceutical composition for use in the treatment of diabetes
EA201890058A1 (ru) * 2015-06-30 2018-07-31 Ханми Фарм. Ко., Лтд. Производное глюкагона и композиция, содержащая длительно действующий конъюгат этого производного
UY36870A (es) 2015-08-28 2017-03-31 Hanmi Pharm Ind Co Ltd Análogos de insulina novedosos
WO2017052329A1 (en) * 2015-09-24 2017-03-30 Hanmi Pharm. Co., Ltd. Protein complex by use of a specific site of an immunoglobulin fragment for linkage
WO2017116204A1 (ko) 2015-12-31 2017-07-06 한미약품 주식회사 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체
KR102005457B1 (ko) 2016-06-29 2019-07-30 한미약품 주식회사 글루카곤 유도체, 이의 결합체, 및 이를 포함하는 조성물, 및 이의 치료적 용도
RU2764197C1 (ru) 2016-09-23 2022-01-14 Ханми Фарм. Ко., Лтд. Аналоги инсулина с пониженной аффинностью к рецептору инсулина и их применение
JOP20190095A1 (ar) * 2016-10-27 2019-04-28 Janssen Pharmaceutica Nv مركبات ببتيد تيروسين-تيروسين الحلقية كمعدلات لمستقبلات الببتيد العصبي y
CN110291103A (zh) 2016-12-05 2019-09-27 韩美药品株式会社 具有弱化的免疫应答的缀合物
JP2020506932A (ja) * 2017-02-03 2020-03-05 ハンミ ファーマシューティカル カンパニー リミテッド 持続性が増加した生理活性物質の結合体及びその用途
KR101941975B1 (ko) 2017-03-17 2019-01-25 고려대학교 산학협력단 Atpif1을 함유하는 당뇨 치료용 약학조성물
AR111341A1 (es) 2017-03-23 2019-07-03 Hanmi Pharm Ind Co Ltd Un conjugado del análogo de insulina con afinidad reducida para el receptor de insulina y uso del mismo
BR112020002871A2 (pt) 2017-08-15 2020-07-28 Kindred Biosciences, Inc. variantes fc de igg para uso veterinário
CA3084326A1 (en) * 2017-09-28 2019-04-04 Jaehyuk Choi Long-acting conjugates of glp-2 derivatives
WO2019066603A1 (ko) 2017-09-29 2019-04-04 한미약품 주식회사 효력이 향상된 지속성 단백질 결합체
EP4321170A4 (en) * 2021-04-09 2025-07-16 Hanmi Pharmaceutical Co Ltd PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CHRONIC KIDNEY DISEASE CONTAINING A GLUCAGON DERIVATIVE
WO2022266467A2 (en) 2021-06-17 2022-12-22 Dana-Farber Cancer Institute, Inc. Recombinant histone polypeptide and uses thereof
KR20230000682A (ko) 2021-06-25 2023-01-03 한미약품 주식회사 심혈관 질환 또는 신장 기능장애 발생의 위험을 감소시키기 위한 에페글레나타이드

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5401716A (en) * 1987-04-15 1995-03-28 Semiconductor Energy Laboratory Co., Ltd. Method for manufacturing superconducting patterns
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
US5705483A (en) 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
US5424686A (en) 1994-04-20 1995-06-13 Philips Electronics North America Corporation Negative-resistance-compensated microwave buffer
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
US7157555B1 (en) * 1997-08-08 2007-01-02 Amylin Pharmaceuticals, Inc. Exendin agonist compounds
US6924264B1 (en) 1999-04-30 2005-08-02 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
US6815203B1 (en) * 1999-06-23 2004-11-09 Joslin Diabetes Center, Inc. Methods of making pancreatic islet cells
US6756480B2 (en) 2000-04-27 2004-06-29 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
BR0116024A (pt) 2000-12-07 2005-12-13 Lilly Co Eli Proteìna de fusão heteróloga e uso da mesma
US7189830B2 (en) 2001-02-19 2007-03-13 Merck Patent Gmbh Anti-KSA/IL-2 fusion proteins with reduced immunogenicity
US7790681B2 (en) * 2002-12-17 2010-09-07 Amylin Pharmaceuticals, Inc. Treatment of cardiac arrhythmias with GLP-1 receptor ligands
EP1605897B1 (en) * 2003-03-19 2012-07-25 Eli Lilly And Company Polyethelene glycol link glp-1 compounds
MXPA05013565A (es) 2003-06-12 2006-03-09 Lilly Co Eli Proteinas de fusion analogas al glp-1.
DE10352479A1 (de) * 2003-11-07 2005-06-09 Basf Ag Verfahren zur Herstellung von Polymerisatpulvern aus wässrigen Polymerisatdispersionen
ATE555133T1 (de) * 2003-11-13 2012-05-15 Hanmi Holdings Co Ltd Igg fc fragment für einen arzneimittelträger und verfahren zu dessen herstellung
JP2006514649A (ja) * 2003-12-17 2006-05-11 アミリン・ファーマシューティカルズ，インコーポレイテッド 腎症の治療および予防のための組成物
JP2007537142A (ja) 2003-12-18 2007-12-20 ノボ　ノルディスク　アクティーゼルスカブ アルブミン様物質に結合した新規のｇｌｐ−１類似物
JP2008507280A (ja) * 2004-07-21 2008-03-13 アンブレツクス・インコーポレイテツド 非天然コードアミノ酸を用いた生合成ポリペプチド
EA011166B1 (ru) 2004-12-22 2009-02-27 Эли Лилли Энд Компани Композиции слитых белков-аналогов glp-1
WO2006076471A2 (en) 2005-01-12 2006-07-20 Nobex Corporation Bnp conjugates and methods of use
KR100754667B1 (ko) 2005-04-08 2007-09-03 한미약품 주식회사 비펩타이드성 중합체로 개질된 면역글로불린 Ｆｃ 단편 및이를 포함하는 약제학적 조성물
PT1881850E (pt) 2005-05-13 2010-11-26 Lilly Co Eli Compostos peguilados de glp-1

Also Published As

Publication number Publication date
CA2674538A1 (en) 2008-07-10
CN101646451A (zh) 2010-02-10
JP2008169195A (ja) 2008-07-24
TWI413528B (zh) 2013-11-01
CN103435700B (zh) 2015-12-23
EP2114438B1 (en) 2012-08-29
CN103435700A (zh) 2013-12-11
EP2114438A1 (en) 2009-11-11
US20100105877A1 (en) 2010-04-29
RU2436589C2 (ru) 2011-12-20
CN101646451B (zh) 2014-03-26
MX2009007267A (es) 2009-11-11
AU2008203574B2 (en) 2011-12-01
DK2114438T3 (da) 2012-12-17
IL199566A (en) 2016-09-29
ES2394121T3 (es) 2013-01-21
HK1136504A1 (en) 2010-07-02
ZA200904337B (en) 2010-10-27
MY164479A (en) 2017-12-29
EP2114438B8 (en) 2012-10-03
JP5399265B2 (ja) 2014-01-29
KR101058315B1 (ko) 2011-08-22
CN103435699A (zh) 2013-12-11
KR20080064750A (ko) 2008-07-09
US8476230B2 (en) 2013-07-02
AR110853A2 (es) 2019-05-08
AU2008203574A1 (en) 2008-07-10
KR20110092253A (ko) 2011-08-17
PT2114438E (pt) 2012-10-11
CA2674538C (en) 2013-12-17
TW200930408A (en) 2009-07-16
KR101058290B1 (ko) 2011-08-22
CN103435699B (zh) 2015-04-15
KR20100061786A (ko) 2010-06-09
EP2114438A4 (en) 2010-09-01
JP2010515677A (ja) 2010-05-13
AR065639A1 (es) 2009-06-17
RU2009129953A (ru) 2011-02-10
NZ577812A (en) 2012-01-12
WO2008082274A1 (en) 2008-07-10

Similar Documents

Publication Publication Date Title
BRPI0806262A2 (pt) complexo insulinotrópico usando um fragmento de imunoglobulina
Joubert et al. Polycyclic cage structures as lipophilic scaffolds for neuroactive drugs
CY1117656T1 (el) Επιλογες θεραπειας για τη νοσο του fabry
EA200971130A1 (ru) Агонисты гуанилатциклазы, пригодные для лечения желудочно-кишечных нарушений, воспаления, рака и других заболеваний
CY1117869T1 (el) Φαρμακοτεχνικες μορφες για απο του στοματος απελευθερωση προσροφητικων στο εντερο
CY1117312T1 (el) Θεραπευτικη αγωγη συνουκλεϊνοπαθειων
CY1119582T1 (el) Υδατικα παρασκευασματα ινσουλινης, που περιεχουν μεθειονινη
CY1118891T1 (el) Συζευγμα ινσουλινης με χρηση θραυσματος ανοσοσφαιρινης
EA201201446A1 (ru) Пептидные производные, их получение и применение
EA201100947A1 (ru) Растворимые полипептиды, предназначенные для применения при лечении аутоиммунных и воспалительных нарушений
JO2744B1 (en) Cytotoxic agents, including new tomaymycin derivatives and their therapeutic use
CY1118984T1 (el) Παρασκευη ενεργων, ακρως φωσφορυλιωμενων, ανθρωπινων λυσοσωμικων ενζυμων σουλφατασης και χρησεις αυτων
DOP2010000379A (es) Compuestos de insulina lispro pegilada
CY1123398T1 (el) Συνθεση συνδυασμου
WO2009114776A3 (en) Integrin targeting agents and in-vivo and in-vitro imaging methods using the same
HRP20070432B1 (hr) Gastrorezistentne farmaceutske formulacije koje sadrže rifamicin
EA200801930A1 (ru) Биспецифическая молекула, связывающая tlr9 и cd32 и содержащая t-клеточный эпитоп, для лечения аллергий
WO2009112488A3 (en) Polyether polyol dendron conjugates with effector molecules for biological targeting
WO2009117041A3 (en) Use of pyrene to carry peptides across the blood brain barrier
AR089506A1 (es) Un conjugado de glp-2 especifico del sitio que emplea un fragmento de inmunoglobulina
CY1117603T1 (el) Η λιξισενατιδη ως προσθετο στη μετφορμινη στην θεραπευτικη αγωγη του διαβητη τυπου 2
BRPI0814339A2 (pt) composição farmacêutica, kit para a preparação da composição farmacêutica, conjugado, e, métodos de formação de imagem óptica in vivo do corpo de mamíferos, e de detecção, estabilização, diagnóstico, monitoramento do progresso da doença ou monitoramento do tratamento de um estado doentio do corpon dos mamíferos
BR112014016338A2 (pt) polímeros de polioxazolina e processos para a sua preparação, conjugados destes polímeros e usos médicos dos mesmos
Vicent et al. Poly-L-glutamic acid (PGA) aided inhibitors of apoptotic protease activating factor 1 (Apaf-1): an antiapoptotic polymeric nanomedicine
WO2007019478A3 (en) Drug delivery from implants using self-assembled monolayers - therapeutic sams

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: HANMI HOLDINGS CO., LTD. (KR)

Free format text: TRANSFERIDO DE: HANMI PHARMACEUTICAL CO., LTD.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25F Entry of change of name and/or headquarter and transfer of application, patent and certif. of addition of invention: change of name on requirement

Owner name: HANMI HOLDINGS CO., LTD. (KR)

Free format text: A FIM DE ATENDER AS ALTERACOES DE NOME E ENDERECO REQUERIDAS ATRAVES DA PETICAO NO 20120115905/RJ, DE 13/12/2012, E NECESSARIO APRESENTAR MAIS UMA GUIA RELATIVA AO SEGUNDO SERVICO SOLICITADO, ALEM DA GUIA DE CUMPRIMENTO DE EXIGENCIA.

B25D Requested change of name of applicant approved

Owner name: HANMI SCIENCE CO., LTD. (KR)

B25G Requested change of headquarter approved

Owner name: HANMI SCIENCE CO., LTD. (KR)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]